Overview

This trial is active, not recruiting.

Condition treating the meniscally deficient knee.
Treatment nusurface meniscus implant
Sponsor Active Implants
Start date January 2011
End date December 2015
Trial size 150 participants
Trial identifier NCT01712191, 00017

Summary

This is a prospective, multi-center, open label, non-randomized study, evaluating the treating of medial meniscus deficiency with the NUsurface Meniscus Implant.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(No Intervention)
nusurface meniscus implant

Primary Outcomes

Measure
Knee injury and Osteoarthritis Outcome Score (KOOS)
time frame: 24 Months

Eligibility Criteria

Male or female participants from 35 years up to 75 years old.

Inclusion Criteria: 1. Have a degenerative and/or torn meniscus and/or previous meniscectomy as confirmed by diagnostic MRI. 2. Have a pain score of 75 or less on the KOOS pain scale, with 100 being normal. 3. Be in neutral alignment +/- 5 degrees of the mechanical axis. 4. Be between age 35 and 75 at the time of the planned surgery. 5. Be able to be fitted anatomically with a size 30 to 90 NUsurface® device. 6. Have a normal mental status. 7. Be willing and able to attend all follow up visits, complete all study questionnaires, and undergo required X-ray and MRI schedule. 8. Be able and willing to understand and sign the informed consent form. Exclusion Criteria: 1. Have evidence of a Grade IV articular cartilage loss on the medial tibial plateau or femoral condyle that could contact the NUsurface implant 2. Have lateral compartment pain with lateral articular cartilage damage greater than Grade II (OB), and/or a lateral meniscus tear(s) 3. Have a varus or valgus knee deformity > 5 degrees. 4. Have a laxity level of more than II (ICRS), secondary to previous injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL). 5. Have patella instability or non-anatomically positioned patella 6. Have patellar compartment pain and/or patellar articular cartilage damage greater than Grade II (OB). 7. Need a tibial osteotomy at the time of surgery. 8. Have an ACL reconstruction performed less than 9 months before implanting the NUsurface® device 9. Have any type of previously implanted prosthetic meniscus or ligament or knee implant made of plastic. 10. Have a knee flexion contracture > 10 degrees 11. Be unable to flex the knee to 90 degrees 12. Have a leg length discrepancy causing a noticeable limp. 13. Have had a previous major knee condyle surgery 14. Present with insufficiency fractures or avascular necrosis of the medial compartment. 15. Have an active infection or tumor. 16. Have any type of knee joint inflammatory disease including Sjogren's syndrome. 17. Have neuropathic knee osteoarthropathy, also known as Charcot joint. 18. Have any medical condition that does not allow arthroscopy at the point of entry to the knee. 19. Be pregnant or is a female intending to become pregnant during the study period. 20. Be mentally incapacitated. 21. Be a prisoner. 22. Be a patient who has economic incentive not to improve (e.g., workman's compensation patient) 23. Be morbidly Obese (BMI > 35). 24. Is unwilling or unable to have an X-ray, Fluro, or MRI of the affected knee

Additional Information

Official title Treatment of the Medial Meniscus With the NUsurface(R) Meniscus Implant
Trial information was received from ClinicalTrials.gov and was last updated in June 2015.
Information provided to ClinicalTrials.gov by Active Implants.